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Abstract
Background: Several common genetic and environmental disease mechanisms are important for the pathophysiology
behind atopic dermatitis (AD). Filaggrin (FLG) loss-of-function is of great significance for barrier impairment in AD and
ichthyosis vulgaris (IV), which is commonly associated with AD. The molecular background is, however, complex and various
clusters of genes are altered, including inflammatory and epidermal-differentiation genes.
Objective: The objective was to study whether the functional and molecular alterations in AD and IV skin depend directly
on FLG loss-of-function, and whether FLG genotype determines the type of downstream molecular pathway affected.
Methods and Findings: Patients with AD/IV (n=43) and controls (n=15) were recruited from two Swedish outpatient
clinics and a Swedish AD family material with known FLG genotype. They were clinically examined and their medical history
recorded using a standardized questionnaire. Blood samples and punch biopsies were taken and trans-epidermal water loss
(TEWL) and skin pH was assessed with standard techniques. In addition to FLG genotyping, the STS gene was analyzed to
exclude X-linked recessive ichthyosis (XLI). Microarrays and quantitative real-time PCR were used to compare differences in
gene expression depending on FLG genotype. Several different signalling pathways were altered depending on FLG
genotype in patients suffering from AD or AD/IV. Disease severity, TEWL and pH follow FLG deficiency in the skin; and the
number of altered genes and pathways are correlated to FLG mRNA expression.
Conclusions: We emphasize further the role of FLG in skin-barrier integrity and the complex compensatory activation of
signalling pathways. This involves inflammation, epidermal differentiation, lipid metabolism, cell signalling and adhesion in
response to FLG-dependent skin-barrier dysfunction.
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Introduction
Atopic dermatitis (AD; OMIM #605803) is a common chronic,
non-contagious, inflammatory skin disorder. Clinical manifesta-
tions include early onset of dry skin, pruritus, eczema with typical
age-dependent distribution, and personal or family history of
atopic disease [1]. Knowledge of the pathophysiology behind the
disease is emerging, several common genetic, environmental
disease mechanisms and individual trigger factors being of
importance [2]. Central in the pathogenesis are combinations of
inherited and acquired insults thought to alter epidermal structure.
These changes in the physiological skin barrier predispose to
increased allergen presentation and are followed by immune
activation, which in turn has negative consequences for skin-
barrier homeostasis [3]. Impaired homeostasis of the skin leads to
increased trans-epidermal water loss (TEWL) and changes in gene
expression patterns [4] and enzymatic activity [5].
The most common monogenic disorder of keratinisation,
ichthyosis vulgaris (IV; OMIM # 146700), is associated with
AD and related atopic manifestations in up to 50% [6]. This
contrasts with X-linked recessive ichthyosis (XLI; OMIM #
308100), which is due to mutations in the STS gene leading to
accumulation of cholesterol sulphate in the stratum corneum. XLI
occurs almost exclusively in males and may look almost
indistinguishable from IV. However, skin histology and surface
pH differ in the two conditions [7] and no association to AD has
been reported in XLI. In 2006, it was found that mutations in the
FLG gene resulting in filaggrin (FLG) dysfunction are the causative
genetic factor for IV [8]. Following the frequent co-existence of IV
and AD it was also discovered that 20–40% of European and
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This is so far the most significant genetic finding associated with
AD [9]. FLG is important for the structural integrity of the skin,
and other functions are attributed to acidic degradation products
of FLG, e.g. urocanic acid (UCA) and pyrrolidone carboxylic acid
(PCA). These are components of natural moisturizing factors
(NMFs) [10] and contributes to maintaining a low pH in the
stratum corneum (SC) [11].
In addition to FLG dysfunction, it has previously been
demonstrated that the molecular background to the pathogenesis
of AD is complex, and that several clusters of genes, including
inflammatory and epidermal differentiation [4,12] are altered in
lesional AD skin. We set out to study whether the functional and
molecular alterations in AD and IV skin depend directly on FLG
loss-of-function variants, and whether the FLG genotype determine
the type of downstream molecular pathways affected.
Materials and Methods
Patient material
Patients (n=43) with AD (n=35), AD and IV (n=5) and IV
(n=3) together with controls (n=15; subjects without past or
present history of AD, dry skin or other atopic manifestations)
were identified at the dermatology outpatient clinics at Karolinska
University Hospital Solna, Sophiahemmet Stockholm and Up-
psala University Hospital; or recruited from a Swedish family
material with known FLG genotype as described previously [13].
All patients were investigated by a dermatologist performing
clinical examination and recording medical history with a
standardized questionnaire. Inclusion criteria were: age 18–65
years and diagnosed AD and/or IV. Exclusion criteria were
pregnancy; other concomitant skin disease; recent UV-treatment;
or recent use of topical or systemic corticosteroids, systemic
immunosuppressives or systemic retinoids (,4 weeks). AD was
diagnosed according to the UK Working Party’s diagnostic criteria
and the disease severity for AD was assessed using the scoring
atopic dermatitis index (SCORAD) [14]. IV was diagnosed by
clinical examination and genetic testing of the FLG gene, and in
male patients with ichthyosis genetic testing of the steroid
sulphatase (STS) gene to rule out XLI. Other atopic manifestations
such as allergic asthma and allergic rhinoconjunctivitis were
assessed through the questionnaire. Blood samples and punch
biopsies were taken from all patients and controls. Two 3 mm
punch biopsies were obtained from a non-lesional area on each
patients forearm, after local anaesthetic with lidocain hydrochlo-
ride with adrenalin (Astra Zeneca, So ¨derta ¨lje, Sweden). TEWL
was assessed using a Tewameter TM 300 Multi Probe Adapter
(Courage+Khazaka electronic GmbH, Ko ¨ln, Germany) and skin
pH was measured using a skin-pH-Meter PH 905 Multi Probe
Adapter (Courage+Khazaka electronic GmbH). TEWL and pH
were measured from the forearms of patients and controls. The
patients were divided into three groups (AD FLG+/+;A DFLG+/2
and AD/IV FLG2/2) depending on genotype of the four most
prevalent European FLG-mutations [6].
Subjects for microarray analysis. Five patients from each
patient group (AD FLG+/+,A DFLG+/2 and AD/IV FLG2/2)
were randomly selected for microarray analysis after removing
outliers in TEWL and pH. In the AD FLG+/2 group four were
heterozygous carriers of the 2282del4 mutation and one was a
heterozygous carrier of the R501X mutation. In the AD/IV
FLG2/2 group four were homozygous carriers of the 2282del4
mutation and one was a homozygous carrier of the R501X
mutation. All selected patients had AD. The groups were
compared to five healthy controls randomly selected after
removing outliers compared to the rest of the control group
regarding TEWL or pH. They carried no tested FLG mutations.
Ethics. The study was conducted according to Declaration of
Helsinki principles and was approved by the regional ethics
committees at Uppsala University and at Karolinska Institute. All
study participants gave written informed consent.
Genotyping
Genomic DNA was isolated from peripheral blood using
QIAampH DNA mini kit (Qiagen, Hilden, Germany).
FLG genotyping. FLG genotyping was performed with allelic
discrimination in patients and controls for the prevalent European
FLG mutations R501X, S3247X and R2447X. Genomic DNA
was PCR-amplified in 384-well plates. Each well contained 5 ng
genomic DNA, 2.5 ml TaqMan Universal PCR Master Mix,
0.125 ml specific Taqman assay solution and 2.375 mlH 2O. Allelic
discrimination was carried out with the ABI PRISMH 7900HT
Sequence Detection System and the SDS 2.2.1 sequence detection
system program (Applied Biosystems, Stockholm, Sweden).
Primers and PCR conditions for tested FLG mutations were as
described previously [6].
FLG mutation 2282del4 was screened for by direct sequencing
using an overlapping PCR fragment covering this region [8]. In
brief, 50 ng DNA was amplified with 1.25 ml 10 mM dNTPmix
(2.5 mM of each), 2.5 ml1 0 6Rxn buffer - MgCl2,2ml5 0m M
MgCl2, 2.5 ml PCR Enhancer, 0.3 ml PlatinumTaq DNA
Polymerase (Invitrogen, Lidingo ¨, Sweden), 10.45 mlH 20 and
2.5 ml each of forward and reverse primer. Sequencing was
analyzed using an ABIH 3730 DNA Analyzer instrument.
STS genotyping. Multiplex Ligation-dependent Probe
Amplification (MLPA) analysis was run for the STS gene using
the P160 A2 kit (MRC-Holland, Amsterdam, the Netherlands), as
previously described [15] with minor modifications. Typically
100 ng genomic DNA was amplified. The sample was analyzed on
the ABI 3130xl Genetic Analyzer. In addition, exon 1–10 of the
STS gene was sequenced using primers and PCR conditions
previously described in male patients where no deletion was
detected [16].
All primer pairs were confirmed specific by database queries
(using BLAST and BLAT). The polyphen [17] and the Alamut
mutation interpretation software (Interactive Biosoftware, Rouen,
France) was used to predict pathogenicity of single nucleotide
polymorphisms (SNPs) compared to reference sequence.
RNA extraction
Skin biopsies were trimmed of subcutaneous fat prior to
homogenization. The biopsies were placed in 1 ml Trizol
(Invitrogen) and subsequently homogenized using a Polytron
homogenizer. Total RNA was isolated as described elsewhere
[18]. Total RNA concentration was determined with spectropho-
tometric analysis and purity was analyzed by the 260:280
absorbance ratios.
Microarray analysis
Microarray hybridization and scanning. Trizol-extracted
total RNA was purified using the RNeasy MiniKit (Qiagen,
Valencia, CA). Samples were re-quantified with spectroscopy, and
purity was re-analyzed through the 260:280 absorbance ratios.
RNA quality and integrity were assessed and ensured using
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) and
RNA 6000 NanoAssay. Hybridization was performed with
Human Gene 1.0 ST arrays (Affymetrix, Inc, Santa Clara, CA).
Briefly, 100 ng of total RNA from each sample was reverse-
transcribed to complementary DNA (cDNA) using the Ambion
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complementary RNA using in vitro transcription with an
amplification kit. 10 mg purified complementary RNA was used
as a template for another cycle of first-strand cDNA synthesis.
Single-stranded cDNA samples were fragmented and end-labeled
with the Gene Chip WT cDNA Synthesis Kit (Affymetrix).
Approximately 25 ng/ml cDNA was added to the hybridization
cocktail, followed by hybridization with the Human Gene 1.0 ST
Array GeneChip at 45uC for 16 hours. This was then washed
using the Affymetrix Fluidics Station 450. A final step was to
measure probe intensities using the GeneChip Scanner 3000. The
raw intensity data was normalized using Command Console
Software (Affymetrix). The average fluorescence intensity of all
annotated genes was calculated using the Robust Multiarray
Analysis (RMA) algorithm [19], including a quartile normalization
(all arrays are considered to have an equal intensity distribution)
and using a background correction for GC-content.
Microarray gene expression, data processing, quality
control and statistical analysis. The values of individual
probes belonging to one probe set were averaged and normalized
using Partek Genomics Suite 6.4 (Partek Inc., St. Louis, MO,
USA, www.partek.com), from which probes with lowest available
p-value and a known GenBank accession ID correspondence were
selected for functional analysis. The distribution of the intensity
values on the individual arrays was visualized in a signal
histogram. One sample was removed due to deviating intensity
values compared to the other samples. No other obvious outliers
were detected. The intensity values of probe sets specific for the
pre-labeled hybridization controls were analyzed and
corresponded with the expected values. To check overall data
quality, the array contained probe sets for exonic and intronic
regions of reference genes (genes thought to be constitutively
expressed in many different samples). Their probe set intensities
were used to calculate the difference between the area under the
curve of the positive and negative probe sets according to the
manufacturer’s instructions [20].
Genes of interest, all over two-fold up/down-regulated genes
(p,0.0005), were analyzed using the Database for Annotation,
Visualization and Integrated Discovery functional annotation tool
[21] with KEGG pathway analysis.
Functional annotations were also carried out using the
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Redwood
City, CA, http://www.ingenuity.com/), in which gene symbols
and fold changes of the up- and down-regulated genes were
imported.
All microarray data comply with MIAME guidelines and are
deposited in ArrayExpress.
Identification of enriched cytobands. 2292 induced genes
and 2076 repressed genes in the AD groups (Table 1) were
analyzed for their enrichment in human cytoband regions and
gene ontology (GO) terms as defined using the DAVID
bioinformatics resources [21], with an individual cutoff for each
gene of p,0.0005.
Quantitative Real-Time PCR
First strand cDNA was synthesized from 1.5 mg total RNA by
combining oligo(d)T15, random hexamers, buffer and MMLV-
reverse transcriptase (Invitrogen) as previously described [18].
cDNA (5–10 ng total RNA) was subsequently amplified by qPCR
using TaqManH Gene Expression Assays (Applied Biosystems) and
TaqManH Fast Universal PCR Master Mix (26) in a ABI7500Fast
PCR machine (Applied Biosystems). TaqMan gene expression
assays used were FLG (Hs00856927_g1), ITGA3 (Hs00233722_
m1), CD28 (Hs00174796_m1), LAMB3 (Hs00165078_m1),
CTNNA1 (Hs00944792_mH), WAS (Hs00166001_m1), JAM2
(Hs01022013_m1), ITGAE (Hs00559580_m1), PTK2B (Hs00169444_
m1), TLR2 (Hs00152932_m1), STAT2 (Hs01013123_m1), with
ubiquitination factor E4A (Hs01083625_m1), 18S ribosomal
RNA 1 (Hs03928985_g1) and GAPDH (Hs02758991_g1) used
as endogenous controls. Expression levels were measured in
duplicate. For genes with expression below the CT fluorescence
threshold, CT was set at 40 to calculate the relative expression.
Analysis was performed using an ABI PRISM 7500Fast
sequence detection system (Applied Biosystems).
Statistical analysis
To identify differentially expressed genes between the different
experimental groups in the microarray analysis, a two-way analysis
of variance (ANOVA) was performed for each patient group
compared to the healthy control group using Partek Genomics
Suite 6.4. For each comparison between two experimental groups
the fold change of every annotated gene, together with their
corresponding p-value, was exported to Microsoft Office Excel.
For quantitative Real-Time PCR, the relative mRNA expression
and statistical significance were calculated using the REST 2009
software (available at www.qiagen.com) using Fisher’s exact test. For
genes chosen for pathway analysis, significance was corrected with
Bonferroni multiple testing. Statistical significance for SCORAD was
calculated using student’s t -test. P-values,0.05 were considered as
significant.
Results
Genotyping and clinical presentation
Among the included patients (n=43) fourteen carried none of
the prevalent FLG mutations tested and were included in the AD
FLG+/+ group. Fourteen AD patients carried one prevalent
heterozygous FLG mutation (one R501X; thirteen 2282del4) and
were included in the AD FLG+/2 group. Fifteen AD/IV patients
carried either a homozygous or a compound heterozygous FLG
mutation (two R501X; nine 2282del4; one S3247X; two
2282del4/S3247X and one 2282del4/R501X) and were included
in the AD/IV FLG2/2 group (of these fifteen patients, three had
IV phenotype without AD at the time of examination). One
patient was excluded from the AD/IV FLG2/2group after no
FLG mutations were detected, and subsequent STS genotyping
revealed a point mutation, recently published elsewhere [16]. In
the AD FLG+/+ group 78.6% were females, the average age was
56 (range 28–78) and the mean SCORAD was 7.6 (range 0–14.7).
In the AD FLG+/2 group, 64.3% were female, the average age
was 54 (range 28–71) and the mean SCORAD was 15.4 (range
6.2–25.8). For the AD/IV FLG2/2 group 46.7% were female,
Table 1. Number of up- and down-regulated genes in
relation to FLG genotype in AD and AD/IV patients.
Phenotype and genotype Upregulated Downregulated
AD FLG+/+ 131 181
AD FLG+/2 328 429
AD/IV FLG2/2 1833 1466
Total # genes 2292 2076
Genes with a minimum two-fold change and p-values,0.0005 were included.
Top up- and down-regulated genes for included patients depending on FLG
genotype. Genes with minimum 2-fold change and p-value,0.0005 were
included.
doi:10.1371/journal.pone.0028254.t001
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AD patients in this group was 14.1(range 7–44.5). The AD FLG+/+
had significantly lower SCORAD than the AD FLG+/2 and
the AD patients in the AD/IV FLG2/2 group (p=0.02). The
control group consisted 43% females and the average age was 52
(range 24–75).
TEWL and pH
Significantly higher TEWL was observed inthe AD/IV FLG2/2
and AD FLG+/2 than in the healthy control group. The mean
TEWL was higher also in the AD FLG+/+ group, although this did
not reach statistical significance. pH was significantly higher in the
AD/IV FLG2/2 group than in the healthy control group. Mean
pH was higher also for the AD FLG+/2 and FLG+/+ groups,
although this did not reach statistical significance (Fig. 1a).
FLG mRNA expression depending on genotype
All patient -groups showed lower mRNA expression of FLG
than the control group, both with microarray analysis and with
quantitative real-time PCR (qPCR). The mRNA expression levels
were lowest in the FLG2/2 group (array p=0.000008; qPCR
p=0.001), but significantly reduced also in the FLG+/2 (array
p=0.04; qPCR p=0.001) and with qPCR also in the FLG+/+
group (array p=0.59; qPCR p=0.04) than in the healthy control
group (Fig. 1b).
Altered expression profiles in AD
The microarrays representing 28869 annotated genes with
764885 distinct probes were used to identify and compare the gene
expression of AD skin compared to healthy skin, and the difference
in expression pattern depending on FLG genotype. The design of
the Human Gene 1.0 ST array was based on the March 2006
(UCSC hg18, NCBI Build 36) human sequence assembly,
containing over 99 percent coverage of sequences present in the
RefSeq database. A full list of significantly altered genes is
provided as Table S1. Among these, the Partek Genomics suite 6.4
was used to detect 4368 differentially expressed genes (minimum
2-fold change and p-value,0.0005) (Table 1). These differentially
expressed genes were distributed according to the chromosomal
enrichment illustrated in Table S2.
Distribution of differentially expressed genes
The distribution of differentially expressed genes in all patient
groups depends on their FLG genotype (Fig. 2a). Hierarchical
clustering was used to group these differentially expressed genes,
based on similarity in expression across the samples and to group
individuals on the basis of similarities in gene-expression patterns
(Fig. 2b). Each column represents a single array experiment and
clusters from Fig. 2a are marked I–VII, respectively.
Altered pathways for cellular development and
differentiation, inflammatory response and cell-to-cell
signaling in AD/IV skin compared to healthy controls,
regardless of FLG status. Ingenuity Pathway Analysis of
differentially expressed genes for all patient groups reveals a
pathway mapped to inflammatory response that was significantly
induced compared to the control group (Fig. 3). In addition, there
were several altered pathways mapped to cellular development
and differentiation compared to healthy controls (Fig. 3).
Significantly altered pathways depending on FLG
genotype status. In AD/IV skin with FLG2/2 genotype,
several pathways were significantly altered compared to the healthy
control group. Focal adhesion, extracellular matrix receptor
interaction, regulation of actin cytoskeleton and calcium signaling
pathways showed significantly altered expression (Table 2).
In AD skin with FLG+/2 genotype, focal adhesion and
extracellular matrix receptor interaction pathways displayed,
similarly to the FLG2/2 group, a significant deviation compared
to the healthy controls, together with ABC transporting pathway
and actin cytoskeleton regulation (Table 2).
For AD skin without FLG mutations focal adhesion, ECM
receptor interaction and regulation of actin cytoskeleton show a
deviating trend (Table 2), but this was not statistically significant.
For a list of candidate genes mapped to altered pathways
depending on FLG genotype see Table S3.
Figure 1. Mean trans-epidermal water loss (TEWL) (a) and pH (b) and decrease in mRNA expression (c) in the AD FLG+/+,A DFLG+/2
and the AD/IV FLG2/2 group. All groups compared to a healthy control group. Significant changes are denoted with * and ** (p,0.05 and
p,0.01), respectively. All groups had significantly altered FLG expression compared to the healthy control group with qPCR; for the FLG+/+ p=0.04,
the FLG+/2 p=0.001 and the FLG2/2 group p=0.001. From the array expression results the FLG+/+ group was lower but not significant (p=0.59)
whereas the expression was significantly lower in the FLG+/2 (p=0.04) and FLG2/2 groups (p=0.000008).
doi:10.1371/journal.pone.0028254.g001
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Identification of candidate genes. For complimentary
testing of selected significantly differentially expressed genes
mapped in the pathway analysis qPCR was performed from
genes in cytobands previously associated to AD (Table S2 and
Table S3) and with fold changes close to two-fold up- or down-
regulation. Of significantly altered pathways, ITGA3 and CTNNA1
were mapped to focal adhesion, LAMB3 to extracellular matrix
receptor interaction, ITGAE to actin cytoskeleton, JAM2 to tight
junction pathway, VAV1 and CD28 to T cell receptor signaling
pathway, and, PTK2B4 was mapped to calcium signaling pathway;
all mapped using DAVID bioinformatics resources [21] with the
KEGG pathway analysis option. TLR2 and STAT2 represent
genes associated with immunological response mapped using
Ingenuity Pathways Analysis (Fig. 3).
Results of Quantitative Real-Time PCR. To study the
relative expression of candidate genes, qPCR was performed in 40
patients and 13 controls. FLG was significantly down-regulated in
all patient groups (FLG+/+ p=0.043; FLG+/2 p=0.001; FLG2/2
p=0.001) (Fig. 2). CD28 (p=0.007), CTNNA1 (p=0.003) and LAMB3
(p=0.01) were all significantly altered in the AD FLG+/+ group.
STAT2 (p=0.001) was significantly altered in the AD FLG+/2
whereas STAT2 (p=0.01), CTNNA1 (p=0.001), JAM2 (p=0.001)
and CD28 (p=0.001) all were significantly altered in the AD/IV
FLG2/2 group. Further details regarding qPCR expression for these
genes are given in Table S4.
Discussion
FLG was shown to be down-regulated both by microarray
analysis and qPCR in all AD/IV groups compared to the healthy
controls. Although there was a gradient of down-regulation
depending on FLG genotype with the lowest FLG expression in
patients with FLG2/2 genotype followed by the FLG+/2
Figure 2. Top overlapping differentially expressed genes in AD skin (a) and heat map of transcriptional levels of genes in AD skin
and controls (b). Genes with altered expression in patients with FLG wild type genotype (FLG+/+), heterozygote FLG mutation genotype (FLG+/2),
and homozygote FLG mutation genotype (FLG2/2). Clusters containing differentially expressed genes in marked regions I–VII are corresponding
regions in a) and b). A list of p-values and fold changes for all differentially expressed genes are described in Table S1. Hierarchal clustering analysis
was performed in both the gene (row) and experiment (column) dimension. Contrast value for each gene is shown, e.g. the standardized mean
difference between the gene’s expression in the group versus overall expression.
doi:10.1371/journal.pone.0028254.g002
Figure 3. Ingenuity Pathways Analysis showing differentially expressed genes mapped to pathway for inflammatory response (a)
and cellular development and differentiation (b and c) for all patient groups. Each gene mapped to this pathway (marked in grey) show
significant altered expression to this pathway (p-value,0.0005).
doi:10.1371/journal.pone.0028254.g003
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compared to healthy control skin. Recent studies have shown that
pro-inflammatory cytokines may modulate the expression of FLG,
even in patients without FLG mutations, which might be one of the
underlying explanations of our finding [22,23].
Many of the potential AD candidate genes significantly altered
in our study were located in chromosomal regions previously
linked to AD [24] (Table S2), further highlighting these regions as
interesting loci for potential candidate genes involved in AD
susceptibility. The distributions of these differentially expressed
genes in our study depended on FLG genotype, where several
clusters were unique for each group, and others overlapped (Fig. 2).
Genes from these groups are mapped to significantly altered
pathways in each patient group. The functional alterations evident
from the significantly higher TEWL and pH (Fig. 1) in the FLG-
deficient groups may influence the number of induced or repressed
genes involved in tightly regulated processes such as inflammatory
response following a more permeable barrier, as well as enzymatic
activity where the pH level is important [11].
The importance of changes in TEWL and pH has recently been
highlighted in FLG deficient skin; where reduced levels of FLG
degradation products are proposed to increase TEWL and pH;
decreasing stratum corneum hydration and altering enzymatic
activity [25,26]. This may account for alterations in corneocyte
and lipid organization within the SC [26]. Given the frequent
phenotypic overlap between dry skin, IV and AD (evident in our
FLG2/2 group as well); it is proposed that these functional
alterations are important for the pathogenesis in both IV and AD
skin with FLG deficiency. In support of this hypothesis, our AD
patients without FLG mutations displayed lower functional barrier
impairment measured by TEWL, lower pH and significantly lower
mean SCORAD than AD patients with FLG mutations (FLG-
repeat variation may also influence the phenotype [27]. However,
we did not investigate this). In addition, the lowest number of
significantly altered genes was detected in our AD FLG+/+ group.
This suggests a correlation between number of affected genes,
barrier impairment and disease severity among included AD
patients.
Of the many genes previously associated to AD [24] several
were also dysregulated in our array data, such as serine protease
inhibitor kazal-type 5 (SPINK-5), mast cell chymase (CMA1 and
interleukin 4 (IL-4) (Table S1). Any discrepancies regarding
expression of inflammatory mediators commonly found in AD
may at least in part be due to lower expression of these genes in
non-lesional skin. CD28 and STAT2 are two inflammatory markers
that were confirmed to be altered also by qPCR. CD28 has been
suggested to be involved in the inflammatory response in AD [28]
and STAT2 has been described as a candidate gene involved in
mediating pro-inflammatory cytokines [29]. In addition, genes
mapped to adhesion such as CTNNA1, JAM2 and LAMB3 were
also confirmed to be significantly altered. Defects in cell adhesion
have recently been highlighted as important in AD pathogenesis,
with the finding of impairment in tight junctions contributing to
the barrier dysfunction and immune dysregulation [30]. Down-
regulation of tight-junction proteins such as occludin and ZO-1
has also been demonstrated in IV skin recently [26] and tallies
with our gene-expression pattern in FLG-deficient skin (Table S1).
The LAMB3 gene encodes laminin-5, a glycoprotein that anchors
basal cells to the underlying basal membrane [31], whereas
CTNNA1 and JAM2, in addition to their cell adhesion function,
Table 2. Top altered molecular pathways depending on FLG genotype.
AD FLG+/+ # genes p-value
hsa04510:Focal adhesion 30 0.001
hsa04810:Regulation of actin cytoskeleton 29 0.006
hsa04512:ECM-receptor interaction 14 0.02
AD FLG+/2 # genes p-value
hsa04512:ECM-receptor interaction 29 0.000005**
hsa04510:Focal adhesion 52 0.000009**
hsa02010:ABC transporters 19 0.00001**
hsa04810:Regulation of actin cytoskeleton 47 0.002*
hsa04020:Calcium signaling pathway 37 0.01
hsa04660:T cell receptor signaling pathway 23 0.04
hsa04520:Adherens junction 17 0.07
AD/IV FLG2/2 # genes p-value
hsa04070:Phosphatidylinositol signaling system 54 0.0000008**
hsa04510:Focal adhesion 118 0.0000008**
hsa04512:ECM-receptor interaction 57 0.000002**
hsa04810:Regulation of actin cytoskeleton 123 0.000003**
hsa04020:Calcium signaling pathway 100 0.00004*
hsa04660:T cell receptor signaling pathway 64 0.0003
hsa02010:ABC transporters 31 0.0003
hsa04530:Tight junction 71 0.007
All included molecules were selected from Table S1 with matching inclusion criteria and mapped using KEGG Pathway analysis. Bonferroni corrected p-values,0.05 are
indicated by * and Bonferroni corrected p-values,0.005 are indicated by **. Candidate genes mapped to each pathway are outlined in Table S3.
doi:10.1371/journal.pone.0028254.t002
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lymphocyte homing [33], respectively. Interestingly CTNNA1 and
LAMB3 were significantly altered in the AD group without FLG
mutations. The underlying explanation could in part be the effects
of putative down-regulation of FLG also in this group, but as the
expressionofLAMB3didnot reachsignificanceinthe ADFLG2/2
group and neither did CTNNA1 or LAMB3 in the AD FLG+/2
group, other explanations are plausible, including that these genes
are candidates for the primary pathogenesis in AD in addition to
FLG deficiency.
The molecular mechanisms involved in the phenotype of AD
following the functional barrier impairment in our material
involve altered pathways such as cytoskeleton structure, calcium-
and phospatidylinositol signaling and ATP binding cassette (ABC)
transport system (Table 2). It has been suggested that FLG is of
importance for cytoskeleton organization by aggregating keratin
intermediate filaments (KIFs); and that FLG deficiency may cause
cytoskeleton abnormalities such as perinuclear keratin retraction
in granular cells [26]. KIF polymerization is actin-dependent [34]
and subsequently actin-cytoskeleton aberrations may contribute to
the peripheral KIF retraction previously demonstrated in FLG-
deficient skin [26]. However, the role of FLG in impaired
intermediate filament aggregation has been challenged [35] and
other factors than FLG deficiency may explain the alterations in
the pathway for the regulation of the actin cytoskeleton. Our
findings support this, as pathways for actin-cytoskeleton regulation
were altered in all our patient groups including the group without
FLG mutations. In addition, several keratins (including KRT1 and
KRT10) were significantly down-regulated in AD patients both
with and without FLG mutations (Table S1). As the actin filament
system has been suggested to be involved in KIF transport [34], it
is possible that increased actin cytoskeleton regulation is a
compensatory mechanism following a lower keratin expression.
Altogether, our data suggests that both keratin expression and KIF
regulation are subject to modulation in AD skin independently of
FLG mutations.
FLG may be involved in calcium metabolism in the skin [36],
and the calcium gradient is important for epidermal differentiation
- a loss of this gradient increases keratinocyte proliferation and
decreases differentiation [37]. Impaired calcium metabolism has
been demonstrated in other conditions where the skin barrier is
disrupted, such as Hailey-Hailey disease [38] and in psoriatic skin
[39]. Further, defective lipid transportation and defects in lamellar
body extrusion have previously been reported in AD [40,41] and
mutations in this pathway may cause severe ichthyotic conditions
such as Harlequin Ichthyosis [42]. Our FLG-deficient groups
show alterations both in the pathway for calcium signaling and for
ABC transport system, indicating that alterations in these
pathways are involved in the pathogenesis of IV and AD with
FLG deficiency.
In conclusion, we have demonstrated that several functional and
molecular mechanisms in vivo in patients suffering from AD and IV
depend on FLG genotype. Disease severity of AD, the gradient of
TEWL and pH follow loss of FLG expression in the skin; and the
number of altered genes and pathways may be correlated to FLG
mRNA expression. We here emphasize further the role of FLG for
the functional integrity of the skin barrier and the complex
subsequent signaling systems involving inflammation, epidermal
differentiation, lipid metabolism, cell signalling and adhesion that
are affected in response to FLG deficiency.
Supporting Information
Table S1 Human Gene 1.0 ST array mRNA expression.
P-values and fold change of each annotated gene are mean values
of five subjects from each patient group (FLG+/+, FLG+/2 and
FLG2/2) compared to a five subjects from the healthy control
group (using the March 2006: UCSC hg18, NCBI Build 36).
(XLSX)
Table S2 Enrichment of chromosomal regions in all AD
patients. Chromosomal regions (cytobands) enriched in 2292
induced genes and 2076 repressed genes using DAVID bioinfor-
matics resource. Cytobands are sorted by p-value and previously
described genetic association to AD is marked yellow.
(DOCX)
Table S3 Candidate genes mapped to altered pathways
depending on FLG genotype. Each annotated gene with
corresponding p-value and fold change depending on FLG
genotype and corresponding cytoband. Cytobands with previously
reported AD association marked with yellow.
(DOCX)
Table S4 Quantitative Real-Time PCR mRNA expres-
sion depending on FLG genotype. Selected genes with
corresponding p-values and ratio of up- or down regulation in
patient groups depending on FLG genotype compared to a healthy
control group.
(XLS)
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